Immunocore Holdings plc (IMCR)

60,23 +0,77 (+1,29%) Alla chiusura: 04:00PM EDT

Immunocore Holdings plc

92 Park Drive
Milton Park
Abingdon OX14 4RY
United Kingdom
44 12 3543 8600
https://www.immunocore.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 497

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Bahija Jallal Ph.D.	CEO & Executive Director	1,38M	9,72M	1961
Mr. Brian R. Di Donato M.B.A.	CFO & Head of Strategy	654,46k	19,48M	1967
Ms. Tina St. Leger	Chief Human Resources Officer	509,12k	790,91k	1968
Dr. David Berman M.D., Ph.D.	Head of Research & Development	796,62k	17,1M	1971
Mr. John Trainer M.B.A.	SVP & Chief Operating Officer	N/D	N/D	1974
Mr. John Goll III	SVP, Finance & Chief Accounting Officer	N/D	N/D	N/D
Ms. Annelise Vuidepot Ph.D.	CTO and Head of Pipeline & Platform Research	N/D	N/D	N/D
Mr. Sean D. Buckley	VP & Chief Information Officer	N/D	N/D	1983
Clayton Robertson	Head of Investor Relations	N/D	N/D	N/D
Ms. Lily Margaret Hepworth	General Counsel & Company Secretary	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di Immunocore Holdings plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.